NewAmsterdam Pharma Confirms Nasdaq Listing for Shares & Warrants

TL;DR

**NewAmsterdam Pharma's shares and warrants are officially listed on Nasdaq under NAMS.**

AI Summary

NewAmsterdam Pharma Company N.V. filed an 8-K on January 4, 2024, to disclose that its Ordinary Shares, with a nominal value of €0.12 per share, are registered for trading on The Nasdaq Stock Market LLC under the symbol NAMS. The filing also notes that warrants are registered. This matters to investors because it confirms the company's continued listing and trading on a major exchange, providing liquidity and visibility for their investment.

Why It Matters

This filing confirms the continued listing of NewAmsterdam Pharma's shares and warrants on Nasdaq, ensuring market access and liquidity for investors.

Risk Assessment

Risk Level: low — This filing is a routine disclosure confirming existing listing information and does not introduce new financial risks.

Analyst Insight

This filing is a standard disclosure confirming listing details. Smart investors would use this to verify the company's trading status and ensure their brokerage accounts reflect the correct ticker for NAMS shares and warrants.

Key Numbers

• €0.12 — Nominal value per Ordinary Share (This is the stated par value of each ordinary share.)

Key Players & Entities

• NewAmsterdam Pharma Company N.V. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where securities are registered
• NAMS (company) — the trading symbol for Ordinary Shares
• €0.12 (dollar_amount) — nominal value per Ordinary Share
• January 4, 2024 (date) — date of earliest event reported and filing date

FAQ

Filing Documents

• d822244d8k.htm (8-K) — 28KB
• d822244dex991.htm (EX-99.1) — 24KB
• 0001193125-24-001933.txt ( ) — 213KB
• nams-20240104.xsd (EX-101.SCH) — 3KB
• nams-20240104_def.xml (EX-101.DEF) — 13KB
• nams-20240104_lab.xml (EX-101.LAB) — 22KB
• nams-20240104_pre.xml (EX-101.PRE) — 14KB
• d822244d8k_htm.xml (XML) — 6KB

01

Item 7.01 Regulation FD Disclosure. On January 4, 2024, NewAmsterdam Pharma Company N.V. issued a press release highlighting its strategic priorities and anticipated milestones for 2024. A copy of the press release is furnished as Exhibit 99.1 hereto. The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: January 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR